By Lauran Neergaard

Hospital workers begin unloading precious frozen vials of COVID-19 vaccine Monday, with the first vaccinations against a scourge that has killed nearly 300,000 Americans expected later in the day.

“It feels like the cavalry is arriving,” Robert C. Garrett, CEO of Hackensack Meridian Health, said as New Jersey’s largest health network awaited delivery.

Shots made by Pfizer Inc. and its German partner BioNTech are the first authorized for emergency use by the Food and Drug Administration -- beginning what will become the largest vaccination campaign in U.S. history. Several other countries also have OK'd the vaccine, including the U.K., which started vaccinating last week.

For health care workers who, along with nursing home residents, will be first in line for vaccination, hope is tempered by grief and the sheer exhaustion of months spent battling a coronavirus that still is surging in the U.S. and around the world.

“This is mile 24 of a marathon. People are fatigued. But we also recognize that this end is in sight,” said Dr. Chris Dale of Swedish Health Services in Seattle.

Packed in dry ice to stay at ultra-frozen temperaturesthe first of nearly 3 million doses being shipped in staggered batches this week made their way by truck and by plane around the country Sunday from Pfizer’s Kalamazoo, Michigan, factory. Once they arrive at distribution centers, each state directs where the doses go next.

Some hospitals across the country spent the weekend tracking their packages, refreshing FedEx and UPS websites for clues.

More of the Pfizer-BioNTech vaccine will arrive each week. And later this week, the FDA will decide whether to green light the world’s second rigorously studied COVID-19 vaccine, made by Moderna Inc.

Now the hurdle is to rapidly get vaccine into the arms of millions, not just doctors and nurses but other at-risk health workers such as janitors and food handlers — and then deliver a second dose three weeks later.

“We’re also in the middle of a surge, and it’s the holidays, and our health care workers have been working at an extraordinary pace,” said Sue Mashni, chief pharmacy officer at Mount Sinai Health System in New York City.

Plus, the shots can cause temporary fever, fatigue and aches as they rev up people's immune systems, forcing hospitals to stagger employee vaccinations.

A wary public will be watching closely to see whether health workers embrace vaccination. Just half of Americans say they want to get vaccinated, while about a quarter don’t and the rest are unsure, according to a recent poll by The Associated Press-NORC Center for Public Health Research.

The FDA, considered the world’s most strict medical regulator, said the Pfizer-BioNTech vaccine appears safe and strongly protective -- and laid out the data behind it in a daylong public meeting last week for scientists and consumers alike to see.

“Please people, when you look back in a year and you say to yourself, ‘Did I do the right thing?’ I hope you’ll be able to say, ‘Yes, because I looked at the evidence,’” Dr. Francis Collins, director of the National Institutes of Health, said Sunday on NBC’s Meet the Press. “People are dying right now. How could you possibly say, ‘Let’s wait and see.’”

Still, emergency use means the vaccine was cleared for widespread use before a final study in nearly 44,000 people is complete -- and that research is continuing to try to answer additional questions. While effective against COVID-19 illness, it’s not yet clear if vaccination will stop the symptomless spread that accounts for half of all cases.

The shots still must be studied in children, and during pregnancy. But the American College of Obstetricians and Gynecologists said late Sunday that vaccination should not be withheld from pregnant women who otherwise would qualify.

While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not to give it to those with a known history of severe allergic reactions to any of its ingredients.

AP journalists Tamara Lush and Kathy Young contributed to this report.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Stoke Space Technologies Raises $65 Million to Develop Reusable Rockets
Reusable rocket developer Stoke Space Technologies raised $65 million in a Series A round led by Breakthrough Energy Ventures, a firm founded by Bill Gates. Stoke says its reusable rockets provide the satellite industry with low-cost, on-demand access to and from orbit. As companies like SpacX and Blue Origin are also making commitments to rocket reusability, Stoke says it is taking a different approach with a system designed to be 100% reusable, comprised of rockets designed to fly daily, like an airplane. Stoke co-founder and CEO Andy Lapsa joins Cheddar News' Closing Bell to discuss.
NASA's Artemis Program to Return Mankind to the Moon, Pave Way for Exploration of Mars
Humans are set to return to a place we have not been in nearly 50 years: the moon. NASA's Artemis program is expected to have astronauts back on the lunar surface by 2025. NASA says it will use what it learns on the moon to take the next giant leap - sending the first astronauts to Mars. The Artemis program also includes contributions from private companies like SpaceX, as well as academic research institutions like Georgia Tech. Georgia Tech professor of practice and former NASA astronaut Sandra Magnus joins Future of Space: Humankind's Leap Forward to discuss.
Clearing the COVID-19 Confusion
The CDC warns that COVID-19 is rapidly spreading with Omicron variant cases doubling every two days in the United States. How do current vaccines hold up against the new strain, and what does it mean for your upcoming holiday travel? Cheddar News breaks things down with infectious diseases specialist Dr. William Schaffner of Vanderbilt University School of Medicine.
U.S. Omicron Cases Surge as People Gear Up for Holiday Travel
President Joe Biden is expected to meet with his COVID-19 response team as the omicron variant continues to surge across the country. Experts say Delta is driving this surge but Dr. Anthony Fauci says Omicron will take over. Emergency physician Dr. Daniel Fagbuyi joins Cheddar News to discuss.
Covid Cases Surge As Omicron On Course To Become Dominant Strain
Omicron is on course to become the dominant COVID strain in the U.S., even as Delta is causing another spike in cases. According to Johns Hopkins University data, cases across the country are up 40% from last month, with New York City as a major hotspot. Outbreaks are now causing Broadway performances to be canceled, colleges and universities to shift to online classes, sports leagues to postpone games, and more. Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to discuss the surge in cases and how we can best protect ourselves against the new variant.
Load More